Valneva Bounces Back From UK Snub With EU COVID-19 Vaccine Deal
Will Supply Up To 60 Million Doses.
The European Commission has approved a purchase deal for Valneva’s COVID-19 vaccine candidate just months after the UK scrapped its own deal with the firm.
You may also be interested in...
Less than a year after signing a major advance purchase agreement to supply its inactivated COVID-19 jab to the EU, Valneva is faced with a termination that could hit its 2022 guidance.
Also, Cytovia will go public via SPAC merger, Nkarta capitalized on its positive early NK cell therapy data with a $230m offering, and venture capital mega-rounds include $220m for Reify, $110m for Satellite Bio and $100m for OMass Therapeutics.
More generic deals but also US approval hurdles for Merck's oral antiviral, while Japan approves more options and Valneva's vaccine candidate shows promise against Omicron.